Portfolio Manager Factsheet
Political rhetoric about an unlikely strategy to provide free healthcare, adversely affected high growth, small & medium cap healthcare stocks. Takeda Pharmaceutical was lower after the company's expected restatement of earnings to include acquisition costs for their merger with Shire. We expect a full recovery in the share price (and then some) as we anticipate the next catalyst for Takeda, namely the presentation of financial guidance for 2019 and beyond, to be announced in May.
Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.